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Background: Month-long daytime Ramadan fasting pose s major challenges to multiple sclerosis (MS) patients in
Muslim countries. Physicians should have practical knowledge on the implications of fasting on MS. We present a
summary of database searches (Cochrane Database of Systematic Reviews, PubMed) and a mini-symposium on
Ramadan fasting and MS. In this symposium, we aimed to review the effect of fasting on MS and suggest practical
guidelines on management.
Discussion: In general, fasting is possible for most stable patients. Appropriate amendment of drug regimens,
careful monitoring of symptoms, as well as providing patients with available evidence on fasting and MS are
important parts of management. Evidence from experimental studies suggests that calorie restriction before disease
induction reduces inflammation and subsequent demyelination and attenuates disease severity. Fasting does not
appear to have unfavorable effects on disease course in patients with mild disability (Expanded Disability Status
Scale (EDSS) score ≤3). Most experts believed that during fasting (especially in summer), some MS symptoms
(fatigue, fatigue perception, dizziness, spasticity, cognitive problems, weakness, vision, balance, gait) might worsen
but return to normal levels during feasting. There was a general consensus that fasting is not safe for patients: on
high doses of anti-convulsants, anti-spastics, and corticosteroids; with coagulopathy or active disease; during attacks;
with EDSS score ≥7.
Summary: These data suggest that MS patients should have tailored care. Fasting in MS patients is a challenge that
is directly associated with the spiritual belief of the patient.
Keywords: Ramadan fasting, Multiple sclerosis, Calorie restrictionBackground
Several religions mention periods of fasting in their re-
spective holy books. A demographic study in 2009 reported
that 23% (1.57 billion) of the world population is Muslim
[1]. This percentage is growing by ≈3% per year. Fasting
during the holy month of Ramadan is considered to be one
of the five pillars of Islam. During Ramadan, Muslims are
forbidden from eating, drinking, smoking, and sexual con-
gress from dusk to dawn. Travelers, women who are men-
struating, pregnant or lactating, children as well as the sick
and disabled are exempt from fasting [2]. However, many
Muslims who are eligible for exemption (including individ-
uals with mild, moderate, and severe medical conditions)
choose to fast. Moreover, recent evidence suggests that* Correspondence: msahrai@sina.tums.ac.ir
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unless otherwise stated.there is no contraindication to Islamic fasting for patients
with mild coronary artery disease, valvular problems, stable
asthma, type-2 diabetes mellitus (T2DM), asymptomatic
peptic ulcers, and intestinal motility disorders. Conse-
quently, Muslim patients with various medical disor-
ders are seeking advice about the safety and feasibility of
fasting [3].
Multiple sclerosis (MS) is one of these medical con-
ditions. MS is a chronic demyelinating disease with
an unclear etiology. It affects≈2.5 million individuals
worldwide and has been identified as the most com-
mon debilitating neurological disease in young adults
[4]. MS is an immune-mediated inflammatory disease
of the central nervous system (CNS) that, in the most
severe cases, can lead to irreversible disability [5].
The concern for Muslim MS patients is whether
Ramadan fasting might have an unfavorable effect on
disease course. This debate became more heated afterl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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perimental autoimmune encephalomyelitis (EAE). In stud-
ies in humans and animals, the effect of fasting on health is
commonly studied in three forms: calorie restriction (CR),
alternate-day fasting (ADF) and dietary restriction. ADF
and CR can induce similar changes upon metabolism
and physiology. Esquifino et al. reported that CR improves
signs of EAE [6]. Hence, we reviewed the opinions of neu-
rologists involved in the care of MS patients with regard to
the clinical impact of Ramadan fasting on MS irrespective
of their religious beliefs.
For this purpose, we first reviewed current evidence
regarding fasting and MS. Second, we prepared a concise
summary of the points discussed in a mini-symposium
on the effect of fasting on MS patients. In this sympo-
sium, we asked neurologists, nutritionists, and pharma-
cists to present a summary of available evidence as well
as their clinical experiences of fasting and MS. Conse-
quently, we aimed to provide practical guidance for MS
patients who wished to fast with respect to general health,
disability score, level of activity, sex, weight, symptoms
and employment.
Information regarding Ramadan fasting and MS was ob-
tained through the Cochrane Database of Systematic Re-
views and PubMed databases. Relevant abstracted reports
were considered from initiation of these databases to June
2013by combining the term “Ramadan” (476 entries) with
terms specific to each of the topics under investigation.
All relevant abstracts on a “ketogenic diet” (703 items) as
well as “calorie restriction” or “fasting” combined with
the terms “neuroprotection” and” immunity” (38 items)
were reviewed. The results of the mini-symposium were
recorded.
Discussion
Fasting in animal studies
CR with nutritional maintenance has been proposed to
extend lifespan in fruit fly, nematodes, zebra fish, spi-
ders, rodents, and rotifers [7]. In addition to slowing the
aging process, CR has been demonstrated to delay the
onset of atherosclerosis, cardiomyopathies, renal disease,
T2DM, cancers, and respiratory disease [7].
With regard to neurological diseases and fasting, CR
represents the first effective treatment for epilepsy in
medical history [7]. CR results in an increase in the
serum level of the ketone bodyβ-hydroxybutyrate. This
rise in β-hydroxybutyrate level correlates with a sig-
nificant reduction in the vulnerability of hippocampal
neurons to injection of the mineral salt kainite. In the
1920s, the ketogenic characteristics of CR led to the de-
velopment of the high-fat, low-carbohydrate ketogenic
diet (KD) [7]. The antiepileptic properties of KD could
be explained (at least in part)by its anti-apoptotic and
antioxidative properties. Recent studies suggested thatthe pro-apoptotic proteinnuclear clusterindid not accu-
mulate in the hippocampi of KD-fed mice in which
seizures were induced by kainic acid (KA) [8]. KD also
reduced KA-induced cell death in the hippocampus by
reducing caspase-3 levels and blocking the dissociation of
Bcl-2-associated death proteinfrom 14-3-3 proteins [9].
Noh et al. undertook an invitro study on the effect of
acetoacetate (AA) on glutamate cytotoxicity in primary
hippocampal neurons in rats and the mouse hippocampus
cell line HT22. Pretreatment with AA reduced production
of reactive oxygen species in the HT22 cell line. AA also
decreased the appearance of propidiumiodine-positive and
annexin V-positive HT22 cells, which are representative of
necrosis and apoptosis, respectively [10].
Accumulating data suggest that the beneficial effects
of CR are not limited to ketogenic properties. CR per se
has profound neuroprotective effects in animal models
relevant to the pathogenesis of neurodegenerative dis-
orders such as Huntington disease, Parkinson disease,
Alzheimer disease and stroke. Opalachet al. investigated
the effect of 40% lifelong CR on age-related oxidative
damage in peripheral nerves. They found that CR ame-
liorates the age-related accumulation of crosslinked and
oxidized substances in peripheral nerves. CR also atte-
nuated age-related increments in levels of nuclear factor
kappaB (NF-κB), phospho-IkB, and tumor necrosis factor
(TNF)-α [11]. Age-related oxidation of polyunsaturated
fatty acids in myelin results in the formation of hydroxyalk-
enals and hydroperoxidases such as4-hydroxynonenal
(HNE) and malondialdehyde (MDA), which react with
proteins and change their surface hydrophobicity. CR
suppresses age-related increases in the MDA-adducted
proteins of sciatic nerves. CR also reduces HNE-positive
areas throughout axonal and glial compartments [12].
Several other molecular and cellular mechanisms have
also been proposed for the neuroprotective action of CR:
decrease in the mitochondrial production of free radicals
[13]; promotion of antioxidant defense [7]; induction of
bioenergetic compounds [7]; elevation in the activity of
sirtuin [14]; rise in the activity of neurotrophic factors
[15]; increase in the activity of protein chaperones [7];
enhancement of neurogenesis [7]; imposition of anti-in-
flammatory properties [7]; reduction in leptin levels [16];
and reduction of the apoptosis of oligodendrocytes [15].
Each of these molecular and cellular mechanisms makes
CR beneficial by protecting against MS and EAE.
Only three studies on CR in an animal model of MS
(EAE) have been carried out. In two of these studies,
Esquifino et al. found that restricting energy intake by
33% or 66% from 15 days before EAE induction decrease
disease severity in rats [6,17]. Rats in the latter group
were totally protected against EAE. Subjecting rats to
66% CR led to impaired proliferation of lymphocytes,
reduction in the number of CD4+ cells in lymphoid
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In a study by Piccio et al., mice were subjected to 40%
CR from 5 weeks before the induction of disease. They
observed comparable beneficial effects on disease course
[18]. They found that CR worked through enhancement
of the production of endogenous glucocorticoids but not
through suppression of the immune system. In the three
studies mentioned above, three concepts were proposed
for the beneficial effects of CR.
Concept 1: improving immune function
Long-term CR improves T-cell function and delays im-
mune senescence. According to a study by Squifino et al.,
66% CR results in modification of the 24-hrhythmicity of
lymph nodes infected by tuberculosis, T cells, functions of
CD4 + −CD8+ and CD4+ cell subsets, as well as mitogenic
responses in lymph nodes to concanavalin A and lipopoly-
saccharide. Furthermore, mean values of the submaximal
lymph-node response to concanavalin A and number of
CD4+ cells increased. Conversely, the number of B-cells
and secretion of IFN-γ decreased [17]. In the study by
Piccio et al., 40% CR ameliorated the signs of EAE without
suppression of proliferation of T cells. Long-term CR
reduced susceptibility to infectious diseases by enhancing
T-cell function [18]. Taken together, application of CR be-
fore disease induction protects against EAE by improving
T-cell function.
Concept 2: CR enhances glucocorticoid production
Glucocorticoids have inhibitory effects on the expression
of genes associated with inflammation [15]. Systemic
administration of corticosteroids exacerbates MS [19]. In
rodents, treatment with exogenous glucocorticoids blocks
EAE [20]. In the study by Piccio et al., 4-week CR in-
creased corticosterone levels [18]. Interestingly, endogen-
ous production of corticosterone avoids the side-effects
reported in the exogenous administration of corticoste-
roids [18].
Concept 3: imposition of an immunomodulatory effect
Interleukin 6 (IL)-6 can be produced by adipose tissue.
Four weeks of CR has been shown to reduce body fat and,
consequently, IL-6 levels. IL-6 has a critical role in EAE
induction [18]. IL-6 together with transforming growth
factor (TGF)-β has been reported to inhibit the pro-
duction of T regulatory cells, and results in suppression of
expression of T-helper (Th)-17 genes [18]. Expression of
Th-17 is one of the main features of MS [21].
Fasting in human studies
There is limited evidence about fasting (especially Islamic
fasting and MS). However, the immunomodulatory and
antioxidative properties of fasting have been the subject of
scientific investigations recently.Ahmed T et al. undertook a study on 30% or 10% CR
in 40 healthy overweight men and women over 6 weeks.
They reported that delayed-type hypersensitivity respon-
ses (which reflect cell-mediated immunity) were increased
significantly in both groups. Also, 30% CR reduced pro-
staglandin (PG) E2production and T-cell proliferative
responses to anti-CD3. Moreover, they observed that pro-
liferative T-cell responses to T-cell receptor antibodies
and T-cell mitogens were increased in both groups. They
concluded that CR can also improve T-cell function in
humans [22]. Paliet al. compared the immune function of
12 obese adolescents with healthy, normal-weight adoles-
cents. They found that the IFN- γ/IL-4 ratio in CD4+ cells
was higher in obese individuals. They proposed that the
antigen presenting cell-regulatory T-cell–CD4+ lympho-
cyte axis might be affected by calorie disturbance [23].
The effect of CR on humans has been studied in a ran-
domized controlled trial sponsored by the USA National
Institute on Aging. Preliminary results showed that 20–
25% CR for 6–12 months reduces levels of leptin, T3 and
fasting insulin. CR also reduces DNA damage as a marker
of oxidative insult [24]. Fraser et al. conducted studies on
the effect of fasting on patients with rheumatoid arthritis.
Rheumatoid arthritis is an autoimmune disease that
shares immunological features with MS. They reported
that 7-day fasting reduced the activity of CD4+ lympho-
cytes and induced IL-4 production [25]. Latifynia et al.
assessed the effect of Ramadan fasting on innate immunity
(tetrazolium reaction in neutrophils and opsonization of
phagocytes). They concluded that the innate immune
response increases after fasting [26].
Fasting and MS
Only two studies on Ramadan fasting in MS patients have
been carried out. El-Dayem and Zyton carried out a study
on 30 MS patients aged 15–45 years with an Expanded Dis-
ability Status Scale(EDSS) score <3. After 1 year, no signifi-
cant differences were observed in relapse rate, EDSS score,
and gadolinium-enhanced lesions on MRI between fasted
and non-fasted groups [27]. Saadatnia et al. undertook a
study on 80 patients aged >17 years with an EDSS score ≤3.
After 6 months, no significant differences in EDSS score or
frequency of clinical relapses were noted between fasted
and non-fasted groups. El-Dayem and Zyton concluded
that fasting does not have unfavorable effects in the short
term. The authors also stated that reduction of food intake
(especially of fat) during Ramadan could enhance antioxi-
dative activity and consequently protect against relapse
after Ramadan. El-Dayem and Zyton also suggested that
reduction of levels of uric acid during Ramadan fasting
could protect against MS relapse. Uric acid is formed as a
metabolite of purine and is concentrated following dehy-
dration during fasting. Serum levels of uric acid are lower
in MS patients compared with healthy individuals [28].
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questions) from points discussed in the mini-symposium
described at the start of this article.Question 1: Is it safe for MS patients to fast?
The effect of fasting on MS is not clear but Islamic fast-
ing is, in general, considered to be safe in most MS
patients. However, making a general recommendation
about the safety of fasting in MS patients is not possible.
The decision should be made with respect to individual
conditions. Ramadan fasting does not appear to have
negative effects on MS patients with mild disability in
the short term [27,28]. Patients should be monitored for
individual symptoms (e.g., fatigue, energy level), type of
MS, level of disability, systemic disease, and medications
taken as well as social skills. Patient education is an im-
portant part of management: they should be informed
about the symptoms associated with exacerbation of MS.Question 2: Does fasting affect MS symptoms?
One of the main concerns is whether fasting affects MS
symptoms. Authors have reported no short-term unfavor-
able effects of fasting on disease course [27,28]. However;
it is believed that during fasting, some of the symptoms of
MS might worsen but return to usual levels during feast-
ing. Symptoms include: fatigue, dizziness, spasticity, cog-
nitive problems, weakness, vision, balance, and gait.
Studies in healthy adults have revealed fasting to induce
fatigue as well as the perception of fatigue. In a study car-
ried out to assess the effect of Ramadan fasting on muscle
power and fatigue in healthy football players after 2 weeks
and 4 weeks of fasting, muscle power was decreased and
fatigue increased in the evening. Moreover, the perception
of exertion and fatigue is higher during Ramadan [29]. It
seems that perceived fatigue is less common in MS
patients who spiritually believe in fasting. However, in
patients who believe fasting to be an obligation, perceived
fatigue might be more prevalent. Moreover, heavy workers
complain about tiredness and dizziness during Ramadan
fasting, which may be due to dehydration [30].
Studies suggest that fasting has no effect on the vision
of healthy adults. In healthy, middle-aged volunteers,
fasting does not affect values of intraocular pressure,
refractive error or visual activity [31]. However, it is
believed that, unlike healthy adults, fasting might affect vi-
sion in MS patients. In a study on judo athletes, Ramadan
fasting had negative effects on postural control: unipodal
and bipodal sway velocity was decreased [32].
Studies on the effects of Ramadan fasting on the mood
profile have elicited mixed results. In a study on eight
middle-distance runners, a 30-day fast negatively affected
the mood profile [33]. In another study on 20 young foot-
ball players, the mood profile did not show significantdifferences during and after Ramadan compared with be-
fore Ramadan [34].
In another study on healthy athletes, changes in cogni-
tive function were studied during Ramadan. The cognition
domains were psychomotor functions, vigilance, visual
learning, verbal learning, memory, and executive function.
Comparison of cognitive function in the morning with the
afternoon showed a significant decline in psychomotor
function, visual and verbal learning, and memory. The
extent of the effect was greater during Ramadan [35].Question 3: Does fasting affect MS exacerbation?
Studies suggest that Ramadan fasting neither protects nor
provokes MS attacks. However, more prospective studies
are needed to follow clinical conditions after Ramadan.Question 4: Can symptomatic treatments be taken during
fasting?
One of the other most frequently asked questions about
fasting in MS patients is whether symptomatic treat-
ments are possible during fasting. It is believed that, for
some drugs, amending the drug regimen is possible dur-
ing Ramadan by substituting oral agents with injections,
or by prescribing slow-release or long-acting drugs once
or twice at night. However, accurate distribution of drugs
prescribed twice a day or three times a day between the
morning meal (Suhoor) and evening meal (Iftar) is
difficult. If dosing and the time span between doses are
changed, these alterations might affectthe serum level of
the drug and, consequently, its tolerability and effi-
cacy [3]. Furthermore, drug–food interactions can re-
sult in delayed, reduced or increased bioavailability of
a drug. Also, changes in circadian rhythms sleep dis-
turbances, emotional stress and physical stress can in-
fluence drug pharmacokinetics. In one study, even
changing the timing of a single dose of valproate
(800 mg) during Ramadan increased the frequency of
seizures significantly [36]. The problem becomes more
notable in patients on polytherapy. Table 1 summarizes
circadian variations in the pharmacodynamics and phar-
macokinetics of commonly prescribed medications for
MS, as well as their drug–food interactions.
It is believed that fasting is not feasible for patients on
high doses of anti-spastic drugs or antiepileptic drugs as
well as patients taking drugs more than twice a day.
Similarly, fasting should be avoided if changing the drug
has negative effects on the activities of daily living or
level of disability. There is also a general consensus
that amending the drug regimen should be started be-
fore Ramadan. In a study on 114 epileptic patients,
amending the drug regimen according to the timing of
Suhoor and Iftar did not prevent an increase in seizure
frequency [42].
Table 1 Circadian variations in pharmacodynamics and pharmacokinetics as well as drug–food interactions of commonly
prescribed MS drugs
Drug Food–drug interaction Recommendation
Baclofen No effect [37].
Dantrolene No effect [38].
Pregabalin Consuming with food decreased Cmaxby 25–30% and
delayedtmaxby ≈3h [39].
Tizanidine Simultaneous food intake with a tizanidinecapsule reduced
Cmaxand AUCo–t by <20% and extendedtmax from 0.75 h
to 1.5 h.
Extent of absorption is increased ≤20% relative to administration
of the tizanidine capsule under fasted conditions.
In contrast,simultaneous food consumption with a tizanidinetablet
increased Cmax and AUCo–t by22.6% and 45.2%, respectively [40].
The dosage forms of the tablet and capsule were not bioequivalent
if administered with food.
Food increasedthe tmax and the extent of absorption for the tablet
and capsule. However, the Cmaxvalues of tizanidine achieved if
administered with food were increased by 30% for the tablet but
decreased by 20% for the capsule. Under fed conditions, the
capsule was ≈80% bioavailable relative to the tablet.
Using tizanidine together with caffeine is, in general, not
recommended. Combining these medications may significantly
increase the blood levels and effects of tizanidine.
Gabapentin High-protein food increased the AUC and Cmaxby 26%
and 32%, respectively [41].
Take extended release tablet with evening meal. Swallow whole;
do not chew, crush, or split.
No significant effects on the rate or extent of absorption of the
immediate-release tablet were noted. The rate and extent of
absorption of the extended-release tablet was increased.
Carbamazepine Serum levels of carbamazepine may be increased if taken with
food and/or grapefruit juice.
Extended-release tablets should be administered with meals;
swallow whole, do not crush or chew.
SSRIs Paroxetine: peak concentration is increased, but bioavailability
is not significantly altered by food.
Sertraline: average peak serum levels may be increased if
taken with food.
AUCo–t, area under the curve from administration (0) to last observed concentration at (t), Cmax, maximum concentration, tmax, time after administration of a drug
when the maximum plasma concentration is reached.
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during fasting?
The pharmacokinetics and pharmacodynamics of inter-
ferons and glatiramer acetate are not affected by food
consumption. Also, it seems that the plasma drug
concentration–time curve of interferons and glatira-
mer acetate are not affected by prolonged fasting
[43,44]. Data on the effect of fasting on the pharma-
cokinetics and pharmacodynamics of fingolimod are
not available. However, according to some neurologists,
fasting is not recommended for patients who experience
severe flu-like symptoms (fever, chills, sweating, muscle
aches, fatigue) after injection of interferons and glatiramer
acetate.
Fasting might affect the pharmacokinetics and pharma-
codynamics of immunosuppressants. Also, drug–food in-
teractions may result in the increased/reduced/delayed
systemic availability of immunosuppressants. Table 2 details
the effects of fasting on the pharmacokinetics and
pharmacodynamics of immunosuppressants and manu-
facturer recommendations for their consumption [45].
Pharmacokinetic and pharmacodynamic reactions betweencyclophosphamide and foods have not been reported.
However, cyclophosphamide is excreted mainly in the
urine, so limited access to liquids during fasting may have
negative effects on drug levels [46].
Question 6: Is the level of disability (EDSS score) important
if a patient decides to fast?
As mentioned above for the data of Saadatnia et al. and
El-Dayem, fasting is known to be safe in patients with
mild disability (EDSS score ≤3) [27,28]. Patients with
higher levels of disability are less physically active. Con-
sequently, they are more prone to constipation, infection
of the upper urinary tract, bedsore, and diverticulitis.
Dehydration during prolonged fasting could aggravate
such symptoms. It is recommended that patients with an
EDSS score ≥7 avoid fasting.
Question 7: Does the type of MS interfere with the
decision to fast?
It is believed that, regardless of the type of MS, patients
with highly active disease should be prohibited from
fasting. Also patients who experience attacks during or
Table 2 Effect of fasting on the pharmacokinetics and pharmacodynamics of immunosuppressants and manufacturer
recommendations for their consumption
Drug Circadian variations in pharmacodynamics and
pharmacokinetics
Manufacturer recommendations
Azathioprine Take after meals or in divided doses for reducing the
risk of stomach upset.
Cyclophosphamide On an empty stomach with a glass of water or juice
or with food.
Tablets are not scored and should not be cut or crushed.
Do not take tablets at bedtime to minimize the risk
of bladder irritation.
Methotrexate Peak serum levels of methotrexate may be decreased if taken
with food. Milk-rich foods may decrease methotrexate absorption.
On empty stomach with plenty of water.
Limit or avoid caffeine intake. Avoid drinks (e.g., coffee,
tea, cola), foods (e.g., chocolate) or diet pills that
contain caffeine.
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tacks, because of the high dose of corticosteroid therapy,
fasting is not recommended.
Question 8: Is fasting during summer safe for MS patients?
The demands of fasting at high latitudes during winter are
different from those in equatorial regions during summer
[47]. Increasing the number of fasting hours during sum-
mer can increase the negative effects of fasting. Individual-
ized monitoring of MS patients who observe fasting during
summer and avoiding dehydration is recommended.
Question 9: Is it safe for MS patients to fast for a whole
month?
The interval between fasting days should be tailored to
the condition of the patient. Appropriate sleep, adequate
and appropriate intake of food and fluids during feasting
hours are recommended. According to Saadatnia et al.,
fasting for 13 h a day for 28 days does not result in un-
favorable short-term effects [28].
Summary
Fasting during Ramadan is an obligation for healthy
Muslim adults. Studies on fasting in MS patients (espe-
cially Islamic fasting) are very rare and have focused on
the protective role of intermittent fasting in MS patients.
There is insufficient evidence to suggest fasting can pro-
tect against or control MS signs, but fasting does not have
unfavorable effects on disease course.
In the mini-symposium discussed above, there is a gen-
eral consensus that observation of Ramadan fasting is pos-
sible for many MS patients. Careful monitoring of general
and clinical conditions as well as precise management of
drug regimens, diet, and sleep patterns will help to reduce
the potential negative effects of fasting. However, fasting
is not recommended during attacks, in patients on
high doses of anti-spastic and anti-convulsant drugs,
or in those with coagulopathy, and EDSS score ≥7, or
active disease.Fasting (especially during summer) might negatively
affect fatigue, weakness, vision, balance, and gait.Individ-
ualized recommendations should be made with respect
to energy level and general wellbeing. It seems that MS
patients who believe in fasting as a sacred obligation
report fewer negative impacts of fasting on MS signs.
For example, perceived fatigue is increased during fasting.
Spiritual belief might reduce the perception of fatigue.
This hypothesis might be expandable to other symptoms
of the disease. Conversely, in patients who find themselves
obliged to fast, the perception of the negative impacts of
fasting might be greater. Patients should be provided with
scientific evidence about the effects of fasting on health
issues before Ramadan to make informed decisions about
fasting.
More studies are needed to prepare detailed guidelines
for MS patients. Our database search and mini-sympo-
sium meeting were attempts to help physicians for the
better care of MS patients who decide to fast, as well as to
pave the way for more research in this field.
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